B-CELL LYMPHOMA ACE-LY-312 (D8227C00001)

Study #ACE-LY-312 (D8227C00001)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects ≤65 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma

Back To Clinical Trials